AMAM

- · NASDAQ

Sector -
Industry -
Website ambrx.com
Employees(FY) 87
ISIN -

Performance

+96.63%

YTD

+166.67%

Profile

Ambrx Biopharma Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing antibody drug conjugates (ADCs) and other engineered therapies to modulate the immune system. It focuses on portfolio of clinical and preclinical programs designed to optimize efficacy and safety in multiple cancer indications, including ARX517, its proprietary antibody-drug conjugate (ADC) targeting the prostate-specific membrane antigen (PSMA) and ARX788, its proprietary ADC targeting HER2. The company also has preclinical and clinical collaborations with multiple partners on drug candidates using Ambrx technology. The company was incorporated in 2003 and is headquartered in La Jolla, California.

Advanced Technical Analysis

Recent News & Updates

2024-03-06 13:20
Ambrx Shareholders Approve Acquisition by Johnson & Johnson(GlobeNewswire)
2024-03-06 00:20
Ambrx Shareholders Approve Acquisition by Johnson & Johnson(Globenewswire)
2024-02-19 20:40
Is Ambrx Biopharma Inc. (AMAM) Stock Outpacing Its Medical Peers This Year?(Zacks)
2024-02-12 00:43
Kuehn Law Encourages AMAM, DOOR, CBAY, and WISH Investors to Contact Law Firm(Prnewswire)
2024-02-07 23:26
Kuehn Law Encourages PGTI, AMAM, JNPR, and GLT Investors to Contact Law Firm(Globenewswire)
2024-01-29 10:02
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates RYZB, FGH, AXNX, AMAM(Prnewswire)
2024-01-25 02:23
Kuehn Law Encourages CPE, ROVR, AMAM, and JNPR Investors to Contact Law Firm(Globenewswire)
2024-01-24 19:03
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates AMAM, HARP, JNPR, TARO(Globenewswire)
2024-01-23 01:45
SHAREHOLDER NOTICE: Halper Sadeh LLC Investigates FGH, AMAM, AXNX(Prnewswire)
2024-01-16 21:42
Kuehn Law Encourages AYX, EGLE, AMAM, and KRTX Investors to Contact Law Firm(Globenewswire)
2024-01-10 02:07
Kuehn Law Encourages AMAM, HARP, AXNX, and CPE Investors to Contact Law Firm(Prnewswire)
2024-01-08 21:25
Global Oncology Cancer Drugs Market Revenue Projected To Surpass $289 Billion By 2030(Globenewswire)
2024-01-08 07:35
Ambrx Announces Sale to Johnson & Johnson(GlobeNewswire)
2024-01-08 01:51
Johnson & Johnson Pays $2 Billion for Ambrx To Boost Its Cancer Drug Pipeline(Investopedia)
2024-01-07 23:22
Why Is Ambrx Biopharma (AMAM) Stock Up 100% Today?(Investorplace)
2024-01-07 22:35
Cramer's Mad Dash: Ambrx Biopharma Inc.(Youtube)
2024-01-07 19:08
Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2B(Yahoo Finance)
2024-01-07 18:35
Ambrx Announces Sale to Johnson & Johnson(Globenewswire)
2024-01-07 18:30
Johnson & Johnson to Acquire Ambrx, Advancing Next Generation Antibody Drug Conjugates to Transform the Treatment of Cancer(Businesswire)
2023-12-14 08:48
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)(GlobeNewswire)
2023-12-13 19:48
Ambrx to be Added to the NASDAQ Biotechnology Index (NBI)(globenewswire)
2023-11-28 08:19
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer(GlobeNewswire)
2023-11-27 19:19
Ambrx Provides Update On APEX-01, an On-Going Phase 1 / 2 Dose Escalation Study Evaluating ARX517, a Proprietary PSMA-Targeting ADC, in Metastatic Castration-Resistant Prostate Cancer(globenewswire)
2023-10-25 22:32
5 Best Performing NASDAQ Stocks in 2023(insidermonkey)
2023-10-23 08:00
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 (â‰¥50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments(GlobeNewswire)
2023-10-22 20:00
Ambrx Announces ARX517, a PSMA-Targeted ADC, Demonstrates a Promising 52% PSA50 ( 50% Reduction) and a Highly Differentiated Safety and PK Profile in Patients with mCRPC, who Progressed on Multiple FDA-Approved Treatments(globenewswire)
2023-10-16 07:56
Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress(GlobeNewswire)
2023-10-15 19:56
Ambrx Provides Safety and Efficacy Data from Ongoing Phase 1/2 APEX-01 Trial of ARX517 in mCRPC at ESMO Congress(globenewswire)
2023-09-30 23:00
Top Stocks for October 2023(investopedia)
2023-09-25 20:30
Ambrx to Host KOL Event Discussing ARX517 Data Presented at ESMO Congress 2023(Yahoo Finance)

Page 1 of 4

previousnext

Disclaimer: The information provided here and on kavout.com site is for general informational purposes only. It does not constitute investment advice, financial advice, trading advice, or any other sort of advice. Kavout does not recommend that any investment decision be made based on this information. You are solely responsible for your own investment decisions. Please conduct your own research and consult with qualified financial advisors before making any investment.